Jump to content
  • rrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    We have completed two surveys with our members and general public.  These surveys were developed with the input of our RRDi Medical Advisory Consultants, and consists of questions of most concern to these doctors when diagnosing rosacea and based upon last year's survey. The more members respond to the survey, the more accurate and complete will be our picture of the rosacea experience of our extensive community, so your input is highly valued by the RRDi.

    To review our survey results click here

    We appreciate your continued support of the RRDi in helping to find a cure for rosacea.

    Thanks very much for your participation.

    Brady Barrows
    RRDi Director

    Joanne Whitehead, Ph.D.
    RRDi Assistant Director
    RRDi Journal Editor in Chief

  • Member Statistics

    Total Members
    Most Online
    Carin Turner
    Newest Member
    Carin Turner

  • Forum Statistics

    • Total Topics
    • Total Posts
  • Posts

    • J Cosmet Dermatol. 2021 Aug 1. doi: 10.1111/jocd.14353. Online ahead of print. ABSTRACT BACKGROUND: Radiofrequency (RF) is a non-invasive or minimally invasive procedure with a low risk of complications. It has been employed for several aesthetic purposes. AIM: This study aimed to conduct a systematic literature review on the use of RF for aesthetic applications and assess the level of accumulated evidence for each condition. METHODS: Using the MEDLINE/PubMed and EMBASE databases, we searched for articles published from 2009 to 2019 describing the use of RF treatment for aesthetic purposes. RESULTS: Our search approach identified 25 randomized clinical trials investigating the efficacy of RF in the following clinical situations: body contour improvement, facial rejuvenation, acne scar treatment, alopecia, and rosacea. There were problems with the quality of the studies, especially regarding selection, performance, and detection bias. CONCLUSION: Our study revealed that RF treatment is potentially promising in all of the evaluated clinical situations; however, we were not able to identify a level of evidence that justifies its use over other therapeutic options currently available on the market. PMID:34333828 | DOI:10.1111/jocd.14353 {url} = URL to article
    • J Cosmet Dermatol. 2021 Aug 1. doi: 10.1111/jocd.14347. Online ahead of print. ABSTRACT BACKGROUND: Centrofacial erythema associated with telangiectasis is the most common presentation of rosacea, known as erythematotelangiectatic rosacea (ETR). However, successful management of these symptoms remains challenging. AIM: The purpose of this study was to evaluate the efficacy and safety of topical timolol maleate eye drops 0.5% for ETR. METHODS: In this randomized, single-center, single-blind, placebo-controlled split-face study, 16 patients with mild-to-moderate ETR who presented at West China Hospital between January 2019 to September 2020 were randomized to receive either topical timolol maleate eye drops 0.5% to one side of their face daily for 28 days and normal saline to the other side of the face. Patients were assessed with both the Clinician Erythema Assessment (CEA) and Patient Self-Assessment (PSA) at the 28-day follow-up appointment. Subjective assessment was performed by asking participants to grade their sensation of warmth and burning. RESULTS: The sides treated with timolol demonstrated a significant improvement in both the CEA and PSA at the 28-day assessment. Patients reported a significant difference in warmth and burning sensations. The only adverse reaction was worsened redness on both sides of the face at Day 1 in one patient. CONCLUSIONS: In this small study, the application of topical timolol maleate was safe and effective for the treatment of ETR. PMID:34333845 | DOI:10.1111/jocd.14347 {url} = URL to article
    • J Med Entomol. 2021 Jul 31:tjab120. doi: 10.1093/jme/tjab120. Online ahead of print. ABSTRACT The prevalence of mites of the genus Demodex and their associations with host age, gender, workplace, and comorbid skin and ocular conditions were studied in participants in Antofagasta, Chile, which is in a region with an extreme environment. We examined 680 participants aged 18-88 yr using standardized surface skin biopsies. Among them, Demodex had a prevalence of 13.5 % (95% confidence interval, 10.88-16.17). A slightly higher prevalence was observed in males (51.1%; 95% confidence interval, 40.9-61.3; nonsignificant) and participants in the 69-88 yr age group (50.0%; 95% confidence interval, 23.8-76.2; P < 0.05). Regarding the species involved, Demodex folliculorum was found in 89.1% (CI 82.7-95.5) of cases, while D. brevis was found in the remaining 10.9% of cases. A higher prevalence (25.0% CI 16.1-33.91) was observed in participants who worked indoors in generally enclosed and dust-rich environments (such as theaters, libraries, and administrative offices). There was also a strong association between Demodex prevalence and conjunctival hyperemia, with 35.9% (95% confidence interval, 9.1-35; OR 17.9) of the Demodex positive participants having this pathology compared to 10.3% of the noninfested participants. In summary, the prevalence of Demodex in Antofagasta, Chile (13.5%) was toward the lower end of the range reported among other regions around the world. Environmental factors such as exposure to the sun (including ultraviolet rays) or environmental pollution may affect the mites. In addition, Demodex genetics (related to virulence) and the ocular or skin microbiota may positively or negatively influence infestation and pathology. PMID:34331059 | DOI:10.1093/jme/tjab120 {url} = URL to article
    • J Am Acad Dermatol. 2021 Jul 27:S0190-9622(21)02180-0. doi: 10.1016/j.jaad.2021.07.031. Online ahead of print. NO ABSTRACT PMID:34329644 | DOI:10.1016/j.jaad.2021.07.031 {url} = URL to article
    • Front Immunol. 2021 Jul 12;12:609615. doi: 10.3389/fimmu.2021.609615. eCollection 2021. ABSTRACT BACKGROUND: Rosacea, a chronic inflammatory skin disorder etiologically associated with immune cells and the antibacterial peptide cathelicidin LL-37, can be effectively treated by oral carvedilol administration. OBJECTIVE: To investigate the molecular mechanisms underlying carvedilol efficacy in rosacea treatment. METHODS: Skin samples of patients with rosacea were subjected to histopathological (hematoxylin and eosin) and immunohistochemical (CD68, Toll-like receptor 2 (TLR2), kallikrein 5, cathelicidin, TNF-α, and IL-1β) evaluation. An in vivo murine rosacea-like inflammation model was established by LL-37 intradermal injection with or without carvedilol gavage-based pretreatment. Erythema proportion (Image J) and skin redness (L*a*b colorimetry) were quantified. Murine skin samples underwent pathological examination for inflammatory status and immunofluorescence staining. Murine skin and lipopolysaccharide-stimulated RAW 264.7 cells with or without carvedilol pretreatment were evaluated by quantitative reverse transcription-polymerase chain reaction and western blotting. Clinical facial images of patients were obtained using the VISIA skin analysis system before, 4, and 6 months following oral carvedilol administration. RESULTS: Rosacea skin lesions exhibited more pronounced inflammatory cell infiltration than peripheral areas, with profound macrophage infiltration and inflammatory cytokines (TLR2, kallikrein 5, cathelicidin, TNF-α, and IL-1β). In vivo, carvedilol alleviated inflammation in LL-37 mice, down-regulating TLR2, KLK5, and cathelicidin expression. In vitro, carvedilol decreased TLR2 expression in RAW 264.7 cells, further reducing KLK5 secretion and LL-37 expression and ultimately inhibiting rosacea-like inflammatory reactions. Clinical manifestations and facial redness obviously improved during 6-month follow-up with systemic carvedilol administration. CONCLUSION: Carvedilol is effective against rosacea, with inhibition of macrophage TLR2 expression as a novel anti-inflammatory mechanism. PMID:34322115 | PMC:PMC8311793 | DOI:10.3389/fimmu.2021.609615 {url} = URL to article More Information on Carvedilol for Rosacea
  • Create New...